[go: up one dir, main page]

WO2012065965A1 - Capuchon pour dispositif d'administration de médicament et procédé de fabrication d'un capuchon pour dispositif d'administration de médicament - Google Patents

Capuchon pour dispositif d'administration de médicament et procédé de fabrication d'un capuchon pour dispositif d'administration de médicament Download PDF

Info

Publication number
WO2012065965A1
WO2012065965A1 PCT/EP2011/070095 EP2011070095W WO2012065965A1 WO 2012065965 A1 WO2012065965 A1 WO 2012065965A1 EP 2011070095 W EP2011070095 W EP 2011070095W WO 2012065965 A1 WO2012065965 A1 WO 2012065965A1
Authority
WO
WIPO (PCT)
Prior art keywords
cap
window section
window
section
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/070095
Other languages
English (en)
Inventor
Lutz Mueller
Michael Helmer
Peggy Rabe
Jörg BIGALKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of WO2012065965A1 publication Critical patent/WO2012065965A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3202—Devices for protection of the needle before use, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
    • A61M2005/3126—Specific display means related to dosing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/16—Making multilayered or multicoloured articles

Definitions

  • Cap for a drug delivery device and method for manufacturing a cap for a drug delivery device
  • a drug delivery device may have a cap which is releasably attachable to a dispensing end of the drug delivery device.
  • a needle assembly located at the dispensing end of the device may be protected by means of the cap.
  • a drug delivery device is described in document EP 1 923 083 A1 , for example.
  • a cap for a drug delivery device may comprise at least one window section.
  • the window section may be configured for displaying information through a wall of the cap.
  • the cap may comprise a non-window section.
  • the window section may be a solid window section of the cap.
  • the non-window section may be a solid non-window section of the cap.
  • both sections, the window section and the non-window section may be solid sections.
  • the cap may be securable against axial and rotational movement with respect to the device.
  • the solid window section may be adapted to enable information located underneath the window section to be viewed by a user when the cap is attached to the device.
  • the solid window section may protect parts of the device located underneath the window section from external influences.
  • the solid non-window section may protect parts of the device located underneath the non-window section from external influences.
  • a further aspect relates to a drug delivery device.
  • the drug delivery device may comprise the previously mentioned cap.
  • the cap may be a unitary component.
  • the cap may be a multi-piece component, e.g. a two-piece component, comprising a solid cap part having an aperture and a solid transparent window insert.
  • the window insert may be secured to the cap part and may extend over the aperture.
  • the drug delivery device may comprise a needle.
  • the needle is expediently, preferably permanently or detachably, mounted to a dispensing end of the device.
  • the cap may be suitable to cover the dispensing end of the drug delivery device.
  • the cap may comprise an opening.
  • the dispensing end of the drug delivery device may be guidable through the opening for attaching the cap to the device, for example by a snap-fit connection.
  • the axial position of the window section may be configured such that the needle could pierce from inside the cap through the window section to the outside of the cap.
  • the length of the needle may be configured such that the needle could pierce from inside the cap through the window section to the outside of the cap.
  • the radial extension of the opening may be configured such that the needle could pierce from inside the cap through the window section to the outside of the cap.
  • the radial extension of a section of the device being arranged adjacent to the dispensing end of the device may be configured such that the needle could pierce from inside the cap through the window section to the outside of the cap.
  • the solid window section may be adapted and arranged to prevent the needle from piercing through the window section from inside the cap to the outside of the cap when the cap is attached to the device.
  • the window section may comprise a thickness which is adapted to prevent the needle from piercing through the window section when the cap is attached to the device.
  • the non-window section may comprise a thickness which is adapted to prevent the needle from piercing through the non-window section when the cap is attached to the device.
  • the thickness of the window section and/or the non- window section is greater than or equal to 0.7 mm.
  • the thickness of the window section and/or the non-window section may be such that a needle comprising a needle gauge equal to or greater than G30 may be prevented from piercing through the window section and/or the non-window section when the cap is attached to the device.
  • a needle comprising a needle gauge of G30 or G32 may be prevented from piercing through the window section and/or the non-window section when the cap is attached to the device.
  • User injuries, caused by the needle protruding through the window section and/or the non- window section may be prevented in this way. Hence, provision of a safely operable drug delivery device is facilitated.
  • a further aspect relates to a method for manufacturing a cap for a drug delivery device.
  • a solid cap part may be formed.
  • at least one solid window section may be defined in the cap part.
  • a cap may be formed comprising the solid window section and a solid non-window section. The cap may enable quick retrieval of important information by means of the window section when the cap is attached to the device.
  • the window section is transparent.
  • the non-window section may be less transparent than the window section.
  • the drug delivery device comprises a cartridge holder.
  • the cartridge holder may be adapted to retain a cartridge.
  • the cartridge may contain a drug.
  • the window section may be adapted and arranged to display information revealed by at least one of the cartridge holder and the cartridge.
  • the cap may be adapted to cover the dispensing end of the device including the needle assembly and at least a part of the cartridge holder.
  • the respective window section may be expediently configured to display information revealed by at least one of cartridge holder and the cartridge when the cap is attached to the device.
  • the cap is a unitary component.
  • the cap may be a single injection moulded piece, for example.
  • the method for manufacturing the cap comprises the step of forming the cap part by injection moulding using a first material.
  • the window section may be defined by injection moulding using a second material.
  • the first material may be less transparent than the second material.
  • the cap part and the window section may be formed together in a single injection moulding process.
  • the cap part is transparent.
  • One of the window section and the non-window section may be defined by freezing a section of the transparent cap part.
  • the other one of the window section and the non-window section may be defined by a non-frozen section of the transparent cap part.
  • the cap in particular the cap part, may be formed in an injection moulding process using one single transparent material, for example. Freezing of a section of the cap part may allow for a flexible definition of the window section, in particular of the shape of the window section.
  • the window section may be elongated. A plurality of window sections may be defined by freezing predetermined sections of the cap part.
  • the method for manufacturing the cap comprises the step of forming the cap part.
  • the cap part may be solid.
  • the cap part may be formed from injection moulding, for example.
  • the cap part may have at least one aperture.
  • at least one solid window insert may be formed.
  • the window insert may be formed from injection moulding, for example.
  • the window insert may be inserted in the window aperture.
  • the window insert may be inserted in the window aperture such that the window aperture is closed by means of the window insert.
  • the window insert may be secured, preferably permanently or releasably secured, to the cap part.
  • the window insert may be secured to the cap part, for example by means of a snap-fit connection, to form the cap.
  • the cap may comprise a two-piece component.
  • the cap may comprise the solid cap part and the solid window insert.
  • the solid window insert may be adapted to prevent the needle from piercing through the window section when the cap is attached to the device.
  • the window insert may be exchangeable.
  • the window insert is transparent.
  • the cap part may be less transparent than the window insert.
  • Information located underneath the aperture may be visible through the transparent window insert. Piercing of the needle through the window section from inside the cap to the outside of the cap may be prevented by means of the solid material of the window insert.
  • a cap for a drug delivery device comprising at least one window section for displaying information through a wall of the cap and a non-window section.
  • the window section is a solid window section of the cap.
  • the non-window section is a solid non-window section of the cap.
  • User-relevant information e.g. the kind of a drug contained in a cartridge of the device, may be effectively displayed by means of the window section when the cap is attached to the device. Additional information, which may confuse the user, located underneath the non-window section may be effectively suppressed.
  • the solid material may prevent a needle, attached to a dispensing end of the device, from piercing through the window section and/or the non-window section.
  • a method for manufacturing a cap for a drug delivery device comprising the steps of forming a solid cap part and defining at least one solid window section in the cap part to form a cap comprising a solid window section and a solid non-window section.
  • the cap facilitates provision of a device with high user safety.
  • needleprick injuries may be prevented by means of the solid window section and/or the solid non-window section which prevent a needle attached to the dispensing end of the device from piercing through the window section and/or the non-window section when the cap is attached to the device.
  • User-relevant information can be retrieved quickly via the window section when the cap is attached to the device. Confusing information may be suppressed by means of the non-window section.
  • Figure 1 schematically shows a perspective side view of an exemplary embodiment of a drug delivery device
  • FIG. 2 schematically shows a part of the drug delivery device of Figure 1 .
  • the drug delivery device comprises a housing 2.
  • the drug delivery device 1 and the housing 2 have a distal end and a proximal end.
  • the term "distal end" designates that end of the drug delivery device 1 or a component thereof which is or is to be arranged closest to a dispensing end of the drug delivery device 1 .
  • the distal end of the device 1 is indicated by arrow 10.
  • proximal end designates that end of the device 1 or a component thereof which is or is to be arranged furthest away from the dispensing end of the device 1 .
  • the proximal end of the device 1 is indicated by arrow 1 1 .
  • the distal end and the proximal end are spaced apart from one another in the direction of an axis.
  • the axis may be the main longitudinal axis 20 of the device 1 .
  • the drug delivery device 1 comprises a cartridge holder 3.
  • the cartridge holder 3 is secured to the housing 2.
  • the device 1 comprises a cartridge 4.
  • the cartridge 4 is retained in the cartridge holder 3.
  • the cartridge holder 3 stabilizes the cartridge 4 mechanically.
  • the proximal end of the cartridge 4 is indicated by a dashed-dotted line.
  • the cartridge 4 may hold a plurality of doses of a drug 18.
  • the drug 18 is preferably a liquid medication, comprising, for example, insulin, like short-acting or long-acting insulin, heparin and/or growth hormones.
  • the term "drug”, as used herein, preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound, wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism
  • the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or
  • the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1 ) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
  • GLP-1 glucagon-like peptide
  • Insulin analogues are for example Gly(A21 ), Arg(B31 ), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin;
  • Des(B28-B30) human insulin Des(B27) human insulin and Des(B30) human insulin.
  • Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N- palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-
  • Exendin-4 for example means Exendin-4(1 -39), a peptide of the sequence H-His-Gly-
  • Exendin-4 derivatives are for example selected from the following list of compounds:
  • H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Lys6-des Pro36 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1 -39)-Lys6-NH2,
  • Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin,
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Goserelin.
  • a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
  • polysaccharides and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • Acid addition salts are e.g. HCI or HBr salts.
  • Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
  • the cartridge 4 has a distally arranged outlet (not explicitly shown).
  • the drug 18 can be dispensed from the cartridge 4 through the outlet.
  • the outlet may be covered by a membrane or septum (not explicitly shown).
  • the membrane may protect the drug 18 against external influences during storage of the cartridge 4.
  • the membrane may seal the outlet fluid-tightly.
  • the drug delivery device 1 may comprise a needle assembly (not explicitly shown), comprising a needle.
  • the needle assembly may be releasably attached to the cartridge holder 3, for example by means of engaging means 5, e.g. a thread.
  • the needle may be in fluid communication with the interior of the cartridge 4.
  • the drug delivery device 1 comprises a bung 7.
  • the bung 7 is moveably retained in the cartridge 4.
  • the bung 7 seals the cartridge 4 proximally. Movement of the bung 7 in the distal direction with respect to the cartridge 4 causes a dose of the drug 18 to be dispensed from the cartridge 4.
  • the device 1 comprises a piston rod 6.
  • the device 1 comprises a drive mechanism (not explicitly shown).
  • the drive mechanism is arranged at least partly within the housing 2 of the drug delivery device 1.
  • the drive mechanism comprises a button 8, e.g. a button 8 actuatable for setting and/or injecting the dose.
  • the drive mechanism is configured to drive the piston rod 6 in the distal direction with respect to the cartridge 4. In this way, a dose of the drug 18 is dispensed from the cartridge 4.
  • the size of the dispensed dose is determined by the distance by which the bung 7 is displaced in the distal direction with respect to the cartridge 4.
  • the drug delivery device 1 may be an injection device.
  • the drug delivery device 1 may be a pen-type device, in particular a pen-type injector.
  • the device 1 may be a disposable or a re-usable device.
  • the device 1 may be configured to dispense fixed doses of the drug 18, in particular doses which may not be varied by the user, or variable, preferably user-settable, doses of the drug 18.
  • the drug delivery device 1 may be a manually, in particular a non-electrically, driven device.
  • the drug delivery device 1 comprises a cap 9.
  • the cap 9 is attachable to the drug delivery device 1.
  • the cartridge holder 3 comprises at least one securing member 12.
  • the cap 9 may be releasably secured, e.g. by a snap-fit connection, to the cartridge holder 3 by means of mechanical cooperation of the securing member 12 and a mating securing member arranged on an inner surface of the cap (not explicitly shown).
  • the securing member 12 may be provided on the housing 2.
  • the cap 9 may be releasably secured against rotational and axial movement with respect to the housing 2 by means of mechanical cooperation of the securing member 12 and the mating securing member.
  • the cap 9 is configured to cover the distal end, in particular the dispensing end, of the drug delivery device 1 including the previously mentioned needle assembly.
  • the cap 9 is configured to cover at least partly the cartridge holder 3 retaining the cartridge 4.
  • the cap 9 comprises a non-window section 17.
  • the non-window section 17 may be a solid section of the cap 9.
  • the non-window section 17 may be an opaque section.
  • the cap 9 comprises at least one window section 13.
  • the cap 9 may comprise two window sections 13 (not explicitly shown).
  • the window sections 13 may be arranged oppositely and/or axially offset with respect to each other (not explicitly shown).
  • the respective window section 13 may be a solid section of the cap 9.
  • the window section 13 may be a transparent section.
  • the cap 9 comprises an opening 16.
  • the opening 16 is adapted and arranged such that the dispensing end of the drug delivery device 1 is guided through the opening 16 for attaching the cap 9 to the device 1 .
  • the cap 9 and the drug delivery device 1 are configured such that the needle could pierce through the window section 13 of the cap 9 when the cap 9 is attached to the dispensing end of the device 1 .
  • the solid window section 13 is adapted to prevent the needle from piercing through the window section 13 which is described later on in more detail.
  • the needle could pass from inside the cap 9 through the window section 13 to the outside of the cap 9 due to the arrangement and/or the configuration of parts of the drug delivery device 1 and/or of the cap 9.
  • one, or two or a plurality of variables may be responsible for the fact that the needle could pass through the window section 13.
  • the variables may comprise the radial extension of the opening 16 with respect to the main longitudinal axis 20. Additionally or alternatively, the variables may comprise the radial extension of a section of the cap 9 which is arranged closer to the distal end of the cap 9 than the opening 16. Additionally or alternatively, the variables may comprise the radial extension with respect to the main longitudinal axis 20 of a section of the device 1 being arranged adjacent to the dispensing end of the device 1 , e.g.
  • the variables may comprise the axial position and/or the axial extension of the at least one window section 13 with respect to the main longitudinal axis 20. Additionally or alternatively, the variables may comprise the length of the needle.
  • the dispensing end of the device 1 and, hence, the needle may be inserted in an inclined fashion into the opening 16 such that the needle could pierce through the window section 13, in particular through a proximal portion of the window section 13, when attaching the cap 9 to the device 1 .
  • This may especially be the case when the device 1 comprises a long needle.
  • the needle when the radial extension of the cartridge holder 3 is smaller than the radial extension of the cap 9 and, in particular of the opening 16, the needle, which was already guided through the opening 16 in an axially aligned fashion, could be put into slope with respect to the main longitudinal axis 20 while attaching the cap 9 to the distal end of the device 1 such that the needle could pass through the window section 13, in particular through a distal section thereof.
  • the solid window section 13 comprises a thickness which is adapted to prevent the needle from piercing through the window section 13 when the cap 9 is attached to the device 1 .
  • the window section 13 may comprise, at least in parts, a thickness greater than or equal to 0.7 mm.
  • the solid non-window section 17 may comprise a thickness adapted to prevent the needle from piercing through the non-window section 17 when the cap 9 is attached to the dispensing end of the device 1 .
  • the non-window section 17 may comprise, at least in parts, a thickness greater than or at least equal to 0.7 mm.
  • the thickness may be suited to prevent a needle comprising a needle gauge of G30 or G32, for example, from piercing through the window section 13 and/or the non-window section 17 when the cap 9 is attached to the device 1 .
  • User injuries caused by the needle protruding through the window section 13 and/or the non-window section 17 may be prevented in this way. Hence, provision of a safely operable drug delivery device 1 is facilitated.
  • Figure 2 schematically shows a part the drug delivery device of Figure 1.
  • Figure 2 shows the cap 9 of the device 1 .
  • the respective solid window section 13 comprises a transparent material.
  • the respective transparent solid window section 13 is configured to display information revealed by at least one of the cartridge holder 3 and the cartridge 4 when the cap 9 is attached to the device 1 .
  • the respective window section 13 may be configured to display information about the content of the cartridge 4, e.g. the type of the drug 18 held in the cartridge 4, which information can be revealed on the cartridge holder 3, for example.
  • the respective window section 13 is adapted and arranged to display information comprising a fill status of the cartridge 4, for example.
  • a plurality of symbols 15 is printed onto the respective window section 13.
  • the symbols 15 may be moulded onto the respective window section 13, for example.
  • the symbols 15 may provide information related to a dosage scale.
  • a plurality of symbols 15 may be printed or moulded onto the cartridge holder 3.
  • the symbols 15 may be visible through the transparent window section 13.
  • the symbols 15 may provide a dosage scale retained on the cartridge holder 3.
  • the respective window section 13 is elongated.
  • the window section 13 may be oriented along the main longitudinal axis 20 of the device 1.
  • the respective window section 13 may comprise a circular shape.
  • the respective window section 13 may comprise a square shape.
  • the shape of the window section 13 may be adapted to the kind of information located underneath the window section 13.
  • An elongated window section 13 may be especially suitable for displaying a row of numbers, e.g. the dosage scale, for example.
  • the non-window section 17 may be less transparent than the window section 13.
  • the non-window section 17 may be opaque.
  • information provided axially and/or rotationally offset from the position of the respective window section 13 may be suppressed by means of the non-window section 17.
  • the suppressed information may be present but invisible for the user when the cap 9 covers the distal end of the device 1.
  • the cap 9 may be a unitary component as mentioned previously.
  • the respective window section 13 and the non-window section 17 may be formed unitarily.
  • a cap part 19 may be formed.
  • the cap part 19 may be solid.
  • at least one window section 13 may be defined in the cap part 19.
  • the window section 13 may be solid.
  • a cap 9 may be formed comprising a solid window section 13 and a solid non-window section 17. As described previously, the solid window section 13 and the solid non-window section 17 may prevent the needle from protruding through the cap 9 when the cap 9 is attached to the device 1 .
  • the cap part 19 may be formed by injection moulding using a first material, for example.
  • the window section 13 may be defined by injection moulding using a second material.
  • the first material may be less transparent than the second material. Accordingly, the cap part 19 and the window section 13 may be formed together in a single 2K injection moulding process. Information located on the cartridge 4 and/or the cartridge holder 3 may be visible through the transparent window section 13.
  • the cap 9 comprising the window section 13 and the non-window section 17 may be formed in an injection moulding process using one single, preferably transparent, material. Therein, the solid cap part 19 may be formed in a first material, for example.
  • the window section 13 may be defined by injection moulding using a second material.
  • the solid cap part 19 may be transparent.
  • the at least one window section 13 may be defined by freezing an area of the cap part 19.
  • the non-window section 17 may be made less transparent than the section of the cap part 19 which was not frozen.
  • the non-frozen section may form the window section 13. Accordingly, a transparent section of the cap part 19, i.e. the window section 13, may be defined by freezing.
  • Freezing of a section of the cap part 19 may allow for a flexible definition of the window section 13, in particular of the shape of the window section 13.
  • a plurality of window sections 13 may be easily defined by abstaining a plurality of predetermined sections from freezing.
  • the cap 9 may be a two-piece component.
  • the cap 9 may comprise the solid cap part 19 comprising the window section 13 and the non-window section 17.
  • the cap 9 may comprise a solid window insert 14.
  • the respective window insert 14 and the non-window section 17 of the cap part 19 may be, releasably or irreleasably secured, for example glued or snap-fitted, to each other.
  • the cap part 19 in a first manufacturing step, may be formed.
  • the cap part 19 may be formed by injection moulding, for example.
  • the cap part 19 is opaque.
  • the cap part 19 is solid.
  • the cap part 19 may have at least one aperture.
  • the position of the aperture may define the position of window section 13 which is to be formed.
  • the aperture may be elongated, for example.
  • at least one solid window insert 14 may be formed, e.g. by injection moulding.
  • the solid window insert 14 may be transparent.
  • the cap part 19 may be less transparent than the at least one window insert 14.
  • the window insert 14 may have a thickness suited to prevent the needle from piercing through the window section 13 of the cap 9 as described previously.
  • the window insert 14 may be adapted and arranged to be introduced into the respective window aperture of the cap part 19.
  • the window insert 14 may be inserted in the window aperture.
  • the window insert 14 may be inserted such that the window aperture and, hence, the window section 13 of the cap part 19, is closed by means of the window insert 14.
  • the window insert 14 may be secured, for example snap-fitted, to the cap part 19.
  • the window insert 14 may prevent the needle from piercing through the window section 13 when the cap 9 is attached to the device 1 .
  • the solid window insert 14 may be exchangeable.
  • a plurality of symbols 15 may be printed onto the solid window insert 14.
  • the symbols 15 may be moulded onto the window insert 14, for example.
  • the symbols 15 may relate to a dosage scale for the drug delivery device 1 as described previously.
  • Other implementations are within the scope of the following claims. Elements of different implementations may be combined to form implementations not specifically described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne un capuchon (9) pour un dispositif d'administration de médicament (1) qui comprend au moins une section fenêtre (13) pour afficher des informations dans une paroi du capuchon (9) et une section non fenêtre (17), la section fenêtre (13) étant une section fenêtre solide du capuchon (9) et la section non fenêtre (17) étant une section non fenêtre solide du capuchon (9). Une épaisseur de la section fenêtre (13) et/ou de la section non fenêtre (17) est supérieure ou égale à 0,7 mm. La présente invention concerne en outre un procédé de fabrication d'un capuchon (9) pour un dispositif d'administration de médicament (1).
PCT/EP2011/070095 2010-11-19 2011-11-15 Capuchon pour dispositif d'administration de médicament et procédé de fabrication d'un capuchon pour dispositif d'administration de médicament Ceased WO2012065965A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10191802.7 2010-11-19
EP10191802 2010-11-19

Publications (1)

Publication Number Publication Date
WO2012065965A1 true WO2012065965A1 (fr) 2012-05-24

Family

ID=44012460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/070095 Ceased WO2012065965A1 (fr) 2010-11-19 2011-11-15 Capuchon pour dispositif d'administration de médicament et procédé de fabrication d'un capuchon pour dispositif d'administration de médicament

Country Status (1)

Country Link
WO (1) WO2012065965A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055619A1 (fr) * 2014-10-09 2016-04-14 Sanofi Boîtier et dispositif d'administration de médicament le comprenant, et procédé de production de boîtier
CN110087714A (zh) * 2016-10-21 2019-08-02 赛诺菲-安万特德国有限公司 液体药剂给予装置
USD985118S1 (en) 2021-03-10 2023-05-02 Amgen Inc. Handheld drug delivery device
USD985117S1 (en) 2021-03-10 2023-05-02 Amgen Inc. Handheld drug delivery device
USD985119S1 (en) 2021-03-30 2023-05-02 Amgen Inc. Handheld drug delivery device
USD985116S1 (en) 2021-03-10 2023-05-02 Amgen Inc. Handheld drug delivery device
USD990668S1 (en) 2020-11-05 2023-06-27 Amgen Inc. Handheld drug delivery device
USD992109S1 (en) 2020-11-05 2023-07-11 Amgen Inc. Handheld drug delivery device
USD1001272S1 (en) 2016-04-28 2023-10-10 Amgen Inc. Autoinjector with removable cap
USD1004078S1 (en) 2019-09-30 2023-11-07 Amgen Inc. Handheld drug delivery device
USD1010107S1 (en) 2020-11-05 2024-01-02 Amgen Inc. Handheld drug delivery device
USD1030040S1 (en) 2020-01-14 2024-06-04 Amgen Inc. Handheld drug delivery device
USD1030041S1 (en) 2020-01-14 2024-06-04 Amgen Inc. Handheld drug delivery device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5797885A (en) * 1997-07-28 1998-08-25 Rubin; Gregory R. Apparatus and method for recapping syringe needles
EP1923083A1 (fr) 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Mécanismes d'entraînement destinés à être utilisés dans des dispositifs d'administration de médicaments
WO2009125582A1 (fr) * 2008-04-10 2009-10-15 パナソニック株式会社 Dispositif d'administration d'un médicament
EP2201970A1 (fr) * 2008-12-23 2010-06-30 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicaments
EP2201974A1 (fr) * 2008-12-23 2010-06-30 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5797885A (en) * 1997-07-28 1998-08-25 Rubin; Gregory R. Apparatus and method for recapping syringe needles
EP1923083A1 (fr) 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Mécanismes d'entraînement destinés à être utilisés dans des dispositifs d'administration de médicaments
WO2009125582A1 (fr) * 2008-04-10 2009-10-15 パナソニック株式会社 Dispositif d'administration d'un médicament
EP2201970A1 (fr) * 2008-12-23 2010-06-30 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicaments
EP2201974A1 (fr) * 2008-12-23 2010-06-30 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MARK PUBLISHING COMPANY
"Rote Liste", 2008

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055619A1 (fr) * 2014-10-09 2016-04-14 Sanofi Boîtier et dispositif d'administration de médicament le comprenant, et procédé de production de boîtier
CN107106770A (zh) * 2014-10-09 2017-08-29 赛诺菲 壳体和具有其的药物输送装置和壳体的生产方法
USD1023290S1 (en) 2016-04-28 2024-04-16 Amgen Inc. Autoinjector with removable cap
USD1001272S1 (en) 2016-04-28 2023-10-10 Amgen Inc. Autoinjector with removable cap
USD1048382S1 (en) 2016-04-28 2024-10-22 Amgen Inc. Autoinjector with removable cap
USD1065512S1 (en) 2016-04-28 2025-03-04 Amgen Inc. Autoinjector with removable cap
US12168115B2 (en) 2016-10-21 2024-12-17 Sanofi-Aventis Deutschland Gmbh Liquid medicament administration device
CN110087714A (zh) * 2016-10-21 2019-08-02 赛诺菲-安万特德国有限公司 液体药剂给予装置
USD1004078S1 (en) 2019-09-30 2023-11-07 Amgen Inc. Handheld drug delivery device
USD1010811S1 (en) 2019-09-30 2024-01-09 Amgen Inc. Handheld drug delivery device
USD1030040S1 (en) 2020-01-14 2024-06-04 Amgen Inc. Handheld drug delivery device
USD1083087S1 (en) 2020-01-14 2025-07-08 Amgen Inc. Handheld drug delivery device
USD1084306S1 (en) 2020-01-14 2025-07-15 Amgen Inc. Handheld drug delivery device
USD1030041S1 (en) 2020-01-14 2024-06-04 Amgen Inc. Handheld drug delivery device
USD990668S1 (en) 2020-11-05 2023-06-27 Amgen Inc. Handheld drug delivery device
USD992109S1 (en) 2020-11-05 2023-07-11 Amgen Inc. Handheld drug delivery device
USD1010107S1 (en) 2020-11-05 2024-01-02 Amgen Inc. Handheld drug delivery device
USD1071163S1 (en) 2020-11-05 2025-04-15 Amgen Inc. Handheld drug delivery device
USD1072240S1 (en) 2020-11-05 2025-04-22 Amgen Inc. Handheld drug delivery device
USD985118S1 (en) 2021-03-10 2023-05-02 Amgen Inc. Handheld drug delivery device
USD985116S1 (en) 2021-03-10 2023-05-02 Amgen Inc. Handheld drug delivery device
USD1071156S1 (en) 2021-03-10 2025-04-15 Amgen Inc. Handheld drug delivery device
USD1097129S1 (en) 2021-03-10 2025-10-07 Amgen Inc. Handheld drug delivery device
USD1073061S1 (en) 2021-03-10 2025-04-29 Amgen Inc. Handheld drug delivery device
USD985117S1 (en) 2021-03-10 2023-05-02 Amgen Inc. Handheld drug delivery device
USD985119S1 (en) 2021-03-30 2023-05-02 Amgen Inc. Handheld drug delivery device
USD1095819S1 (en) 2021-03-30 2025-09-30 Amgen Inc. Handheld drug delivery device
USD1071160S1 (en) 2021-03-30 2025-04-15 Amgen Inc. Handheld drug delivery device

Similar Documents

Publication Publication Date Title
WO2012065965A1 (fr) Capuchon pour dispositif d'administration de médicament et procédé de fabrication d'un capuchon pour dispositif d'administration de médicament
EP2488236B1 (fr) Ensemble support de cartouche pour dispositif d'administration de médicaments
EP2403561B1 (fr) Seringue, dispositif d'auto-injecteur et ensemble de dispositifs d'auto-injecteur et seringues
EP2437824B1 (fr) Mécanisme de configuration de dose pour amorcer un dispositif d'approvisionnement de médicament
EP2482879B1 (fr) Procédé et assemblage pour un dispositif d'administration de médicaments
EP2414012B1 (fr) Capuchon de stylo
WO2011054648A9 (fr) Ensemble porte-cartouche pour un dispositif d'administration de médicament
WO2010112558A1 (fr) Dispositif d'administration de médicaments muni d'une fenêtre d'indication de dose
US20120204662A1 (en) Drive Mechanism and Drug Delivery Device
EP2632512B1 (fr) Dispositif pour l'administration des medicaments et procede pour l'assemblage d'un dispositif pour l'administration des medicaments
EP2654848B1 (fr) Ensemble support de cartouche pour un dispositif d'administration de médicament
HK1188580A (en) Drug delivery device and method for assembling a drug delivery device
HK1188580B (en) Drug delivery device and method for assembling a drug delivery device
HK1166733B (en) Pen cap
HK1167831A (en) Dose setting mechanism for priming a drug delivery device
HK1167831B (en) Dose setting mechanism for priming a drug delivery device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11781820

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11781820

Country of ref document: EP

Kind code of ref document: A1